Multicenter Phase II trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancer.

Trial Profile

Multicenter Phase II trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LOGiK-0802
  • Most Recent Events

    • 01 Jun 2016 Results published in the Anticancer Research
    • 02 Sep 2013 Planned end date changed from 1 Jul 2014 to 31 Jan 2015 as reported by University Hospital Medical Information Network - Japan record.
    • 05 Mar 2013 Planned end date changed from 1 Jan 2014 to 1 Jul 2014 as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top